ANAPTYSBIO, INC - 8-K Filing

AnaptysBio reports Q3 2026 net income of $3.9 million and Jemperli global sales reaching $1.0 billion for the nine months ended September 30, 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 21:16 UTC

Tickers: $ANAB

Read the full article at SEC EDGAR

Part of the story Once Upon a Farm, PBC - 8-K Filing (3 articles)

More Regulatory news

Rain Enhancement Technologies Holdco, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:23 UTC
Star Equity Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:22 UTC
Scribe Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:22 UTC
RMR GROUP INC. - 10-K Filing SEC EDGAR · November 12, 2026, 21:22 UTC
Commercial Vehicle Group, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:22 UTC
CROWN CRAFTS INC - 10-Q Filing SEC EDGAR · November 12, 2026, 21:21 UTC
Avidbank Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:21 UTC
SOLV Energy, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:22 UTC
Cardiff Oncology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:21 UTC
Ensysce Biosciences, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:22 UTC